News Search Results
Apr 01, 2025, 06:00 ET IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
2025 RBCCM Ophthalmology ConferenceThursday, April 3rd, 2025 at 11:30 AM ET Fireside
More news about: IDEAYA Biosciences, Inc.
Apr 01, 2025, 01:49 ET Acer Medical Luncurkan Solusi Pemeriksaan Mata yang Didukung VeriSee AI di Kongres Tahunan Malaysian Ophthalmology Society
Diabetic Retinopathy dan VeriSee Age-Related Macular Degeneration. Kedua inovasi tersebut akan dipamerkan Acer Medical di Kongres Tahunan Malaysian Ophthalmology Society (MSO). Dengan demikian, Acer Medical menghadirkan teknologi pemeriksaan kesehatan AI yang canggih untuk ahli oftalmologi di Malaysia.
More news about: Acer Medical Inc.
Mar 31, 2025, 10:15 ET Clinical Trial Supplies Market worth $8.18 billion in 2030 with 8.9% CAGR | MarketsandMarkets™
disorder/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal, immunological disorder, infectious diseases, psychiatry, ophthalmology, haematology, genitourinary and women's health, and others. Oncology segment dominated the segment in 2024 owing to various factors such as increased
More news about: MarketsandMarkets
Mar 31, 2025, 06:00 ET Global Healthcare Accreditation Certifies Médico Express, Marking a Milestone for Dominican Republic's Health Tourism Industry
ensuring agile and personalized processes. The center offers a comprehensive portfolio of services, including urgent care and outpatient surgery, ophthalmology and gastroenterology units, consultations across more than 40 medical specialties, advanced imaging and clinical laboratory services, dentistry,
More news about: Global Healthcare Accreditation
Mar 30, 2025, 21:19 ET Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products
More news about: Innovent Biologics
Mar 27, 2025, 16:01 ET Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
long-term health engagement and monitoring for both ophthalmic and systemic conditions. We are designing VETi with the intent to disrupt future ophthalmology clinical trials by enabling new trial endpoints, thereby enabling faster and more cost-effective medicines development in ophthalmic disease, an
More news about: Kodiak Sciences Inc.
Mar 27, 2025, 04:00 ET ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach
[email protected] Contact for the press Frank Smith Head of Global Communications Ophthalmology Carl Zeiss Meditec Inc. Phone: +49 3641 220 331 Email: [email protected]
More news about: Carl Zeiss Meditec AG
Mar 27, 2025, 04:00 ET ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach
[email protected] Contact for the press Frank Smith Head of Global Communications Ophthalmology Carl Zeiss Meditec Inc. Phone: +49 3641 220 331 Email: [email protected]
More news about: Carl Zeiss Meditec AG
Mar 27, 2025, 01:29 ET Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Mar 26, 2025, 21:12 ET Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from
More news about: Innovent Biologics
Mar 26, 2025, 17:46 ET VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia Care | DelveInsight
Ocumension limited, Santen Pharmaceutical, Cloudbreak therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, among others.
More news about: DelveInsight Business Research, LLP
Mar 26, 2025, 17:31 ET LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
mutations in the RPE65 gene, it offers hope to patients who previously had limited options. The growing awareness and adoption of gene therapies in ophthalmology, along with advancements in personalized medicine, are expected to expand LUXTURNA's market reach.
More news about: DelveInsight Business Research, LLP
Mar 26, 2025, 09:00 ET Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for its Epigenetic Reprogramming Therapies
aging. The license and associated intellectual property will enable Turn Bio to accelerate the progress of drug candidates in its pipeline for ophthalmology and the rejuvenation of certain immune cells. ARMMs enables the company to advance these candidates alongside TRN-001, a therapy to rejuvenate
More news about: Turn Biotechnologies, Inc.
Mar 26, 2025, 08:58 ET Turn Biotechnologies Acquires ARMMs Vesicular Technology to Increase Access to Tissue Targets for Its Epigenetic Reprogramming Therapies
aging. The license and associated intellectual property will enable Turn Bio to accelerate the progress of drug candidates in its pipeline for ophthalmology and the rejuvenation of certain immune cells. ARMMs enables the company to advance these candidates alongside TRN-001, a therapy to rejuvenate
More news about: Turn Biotechnologies
Mar 26, 2025, 08:30 ET InMode to Present at the 24th Annual Needham Virtual Healthcare Conference
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit https://inmodemd.com/.
More news about: InMode Ltd.
Mar 26, 2025, 08:00 ET Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval,
More news about: Mabwell
Mar 26, 2025, 06:21 ET Innovent Announces 2024 Annual Results and Business Updates
company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2024 annual results, including major business updates, financial performance and the strategy and outlook
More news about: Innovent Biologics
Mar 25, 2025, 10:36 ET Hubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16
several devastating pediatric blindness diseases," Dr. Bikash Pattnaik, professor in the Departments of Pediatrics, Ophthalmology and Visual Science at the University of Wisconsin–Madison, Daniel M. Albert Chair McPherson Eye Research Institute and scientific co-founder of
More news about: Hubble Therapeutics LLC
Mar 25, 2025, 10:36 ET Hubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16
several devastating pediatric blindness diseases," Dr. Bikash Pattnaik, professor in the Departments of Pediatrics, Ophthalmology and Visual Science at the University of Wisconsin–Madison, Daniel M. Albert Chair McPherson Eye Research Institute and scientific co-founder of
More news about: Hubble Therapeutics LLC
Mar 25, 2025, 06:00 ET TFS HealthScience Appoints Miriam Martin as Vice President of Business Development, Clinical Development Services
highlighted by advancements across its core therapeutic areas. The company has recently initiated pivotal early- and late-phase clinical programs in ophthalmology—including studies in diabetic macular edema and other retinal diseases—alongside expanding oncology efforts in pancreatic cancer, non-small cell
More news about: TFS HealthScience
Mar 25, 2025, 06:00 ET TFS HealthScience Appoints Miriam Martin as Vice President of Business Development, Clinical Development Services
highlighted by advancements across its core therapeutic areas. The company has recently initiated pivotal early- and late-phase clinical programs in ophthalmology—including studies in diabetic macular edema and other retinal diseases—alongside expanding oncology efforts in pancreatic cancer, non-small cell
More news about: TFS HealthScience
Mar 24, 2025, 16:41 ET U.S. News & World Report Names CSA's East Bay Surgery Center and Middlesex Endoscopy Center Among "Best Ambulatory Surgery Centers" for Second Consecutive Year
East Bay, an AAAHC-accredited facility in Swansea, Massachusetts, was named in the Best Ophthalmology category. Middlesex, an AAAHC-accredited facility in Middletown, Connecticut,
More news about: Constitution Surgery Alliance
Mar 24, 2025, 16:30 ET Nanoscope Announces Publication of Clinical Data on Vision Restoration in Retinitis Pigmentosa
mutation," said Dr. Vinit B. Mahajan, co-corresponding author and Professor and Vice Chair for Research, Department of Ophthalmology at Stanford University. "The ability to restore vision with a single intravitreal injection marks a significant step toward developing a universal
More news about: Nanoscope Therapeutics
Mar 24, 2025, 12:14 ET Medical Tapes and Bandages Market Surges to USD 8.7 Billion by 2033, Propelled by 6.0% CAGR - Verified Market Reports®
By Application Wound CareSports MedicinePost-operative CareFirst AidOphthalmologyBy End-User HospitalsClinicsNursing HomesHome HealthcareSports
More news about: Verified Market Reports
Mar 23, 2025, 20:00 ET Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative
More news about: Innovent Biologics